Awarener easy mode Awarener analytic mode

Fundamental analysis: BIMI International Medical, Inc. (BIMI)

Awarener score: 3.1

Conclusion

The higher the Awarener score, the more bang you get for the buck. It measures how much genuine funds the company generates for the stock price paid (Very poor), the business stability (Bottom) and growth (Superb), and the company's inclination to return cash to the stockholders (Bottom).

Note: All scores range from 1 (worst) to 10 (best). Conclusions are updated daily with closing stock prices and new reported quarterly financial statements.

Revenue score: 5.5

  • Business has been growing at an extremely fast pace. It's been more than average in relation to peer companies.
  • BIMI International Medical, Inc. business varies wildly, ups and downs could be very frequent. It's very risky. It looks bottom tier against rivals.

Margins score: 2.2

  • BIMI profit margins -on goods and services sold- are usually very poor. They stand bottom tier against rival companies.
  • Business profit on sales tends to be extremely poor. It's last-in-rank when measured against competitors.
  • Profits on sales made -available to repay debt and purchase properties- are usually extremely poor. They remain a disappointment compared to peers.
  • Earnings -before income taxes and interests on loans taken- tend to be extremely poor in relation to total revenues. They're still bottom tier against similar companies.
  • Profits -before income taxes- are usually extremely poor considering total sales, and remain last-in-rank when measured against rivals.
  • Total net profit tends to be extremely poor when confronted to sales. Company stands last-in-rank when measured against comparable firms.

Growth score: 2.3

  • BIMI International Medical, Inc. profit -on goods and services sold- has been growing at an extremely fast pace. It's been a disappointment compared to competitors.
  • In recent years, the firm hasn't always been able to profit from operations, which has been bottom tier against comparable firms.
  • In past years, the company couldn't always turn a profit -available to repay debt and purchase properties-, which compares last-in-rank when measured against peer enterprises.
  • In the previous years, the firm couldn't always make a profit -before income taxes and interests on loans taken-. It turns to be a disappointment compared to similar stocks.
  • In past years, at least once the company lost money -before income taxes-. It was bottom tier against rivals.
  • In the previous years, the firm had at least a total net loss, and last-in-rank when measured against peer companies.
  • The company lost money at least once in the past years. It's been a disappointment compared to industry peers.

Miscellaneous score: 1.0

  • BIMI had still to pay income taxes, even though in recent past years mostly lost money. It's been bottom tier against peers.
  • The company does not report R&D expenses. It's meaningless to measure in relation to competitors.
  • We have insufficient data to estimate how effective is research and development effort. It stands unknown against rival companies.

Profitability score: 2.0

  • BIMI International Medical, Inc. usually gets very poor returns on the resources it controls. It proves weak when measured against peer firms.
  • The company normally gets very poor proceeds -on the resources directly invested in the business-. They remain in a very weak position compared to similar companies.
  • Profitability -in relation to owned resources- is usually insufficient. It ranks weak when measured against competitors.
  • In the past, got very poor returns -on the tangible resources it controls-. This metric is usually related to the industry in which operates and combines profitability versus reinvestment needs. It's weak when measured against comparable enterprises.

Usage of Funds score: 1.2

  • BIMI on average doesn't generate genuine funds, so to buy or replace property, plants and equipment must either burn existing cash or increase debt. It stands weak when measured against rival firms.
  • The company is usually not replacing property, plant, and equipment that gets old, instead using funds in something else. It can't keep forever, which is substantially worse when measured against industry peers.
  • In the past twelve months the stock paid no dividends. It came bottom tier against competitors.
  • The company pays no dividend, so measuring its growth is meaningless. The company has behaved in an conservative way compared to similar firms.
  • As no dividends are paid, it is useless trying to estimate their sustainability in time. Sustainability looks not applicable in regard to comparable companies.
  • The company has greatly enlarged the pool of investors in previous years, resulting in more mouths feeding on the pie of profits. It remains a disappointment compared to peer enterprises.
  • Repurchase effectiveness metric is very complex. Run again in analytical mode if you're interested in a technical explanation. It stands in a very weak position compared to rivals.
  • We do not have sufficient data to comment on buybacks and their sustainability. It still looks dubious against competitors.

Balance Sheet score: 4.4

  • BIMI International Medical, Inc. intangible assets (like brands and goodwill) represent a portion of resources controlled, according to accounting books. There could be difficulties in liquidating them if the company ever gets in financial distress. It happens to be below average when measured against peer companies.
  • The company has somewhat lower short-term resources than short-term obligations. Unless it's part of the business model, there might some liquidity concerns. It turns to be in a very weak position compared to similar firms.
  • Roughly a quarter of resources controlled were provided for with financial debt. Creditors have some claims on the company. It remains slightly better than rival firms.
  • Controlled resources can be made into cash within reason, which is quite good for liquidity. It looks weak when measured against rivals.
  • For every dollar of short-term obligations, the company has less than a dollar of cash and short-term receivables. It's in a very weak position compared to peer firms.
  • For every dollar of short-term obligations, the company has few cents of cash and equivalents, which is worse than most similar enterprises.
  • Usually, sales are on somewhat less than three months credit. It still ranks last-in-rank when measured against peers.
  • Normally has approximately somewhat more than two months of sales worth in inventory. It comes up as rather normal in relation to competitors.
  • On average, it takes higher than five months from the purchase to charging customers. It happens to be bottom tier against peers.
  • On average pays suppliers approximately three months after the purchase. It ranks encouraging in relation to industry peers.
  • The company pays its suppliers roughly one month before charging its customers, so there's sparse money invested in working capital. It's lacking compared to similar companies.
  • Has usually been losing money on the business, so net interest expenses must be paid by increasing borrowings, which is unsustainable in the long run. The situation is very risky for both creditors and shareholders, profitability must increase. It stands bottom tier against rival firms.
  • Business has usually been operated at a loss. Unless prospects improve, the company is no position to decrease loans taken levels but by additional shareholders' funding. Profitability must improve. It ranks last-in-rank when measured against comparable enterprises.
  • Revenues are modest in relation to property, plant, and equipment required to operate. This metric is likely dependent on the industry the company operates in. The more property, plant, and equipment used, the more the company must reinvest to fight obsolescence, which usually means less available funds for the shareholders in the long run. It looks in a very weak position compared to similar firms.
  • Resource exploitation is quite good when yearly sales are considered. This metric is normally tied to the industry where the firm belongs. It's still bottom tier against peer companies.

Valuation score: 3.3

  • BIMI International Medical, Inc. reported losses, so valuating it in relation to earnings is meaningless. It happens to be last-in-rank when measured against competitors.
  • Price-to-Tangible-Book-Value is a fairly complex metric. Run again in analytical mode if you're interested in a technical explanation. It remains close to average when compared to peers.
  • In the past twelve months, the company consumed funds. Either it reinvested significantly in the business or genuine fund generation might be struggling, which stands mediocre against similar companies.
  • The company usually consumes much more funds than can genuinely generate. Business needs are meet by borrowing money or consuming preexistent cash, which can only keep up until a certain limit. Unless the company is driving significant business growth, genuine profitability may be brought into question. It's still weak when measured against industry firms.
  • In the past twelve months, the company has greatly enlarged the pool of investors by issuing new shares. Future profits need to be high enough to justify the measure, as the pie of earnings will now be split among plenty more stockholders. It came up a disappointment compared to peer ventures.
  • The company is indebted, it should focus on loan repayment. It looks somewhat worse than similar enterprises.
  • Considering the past twelve months, traditional Price-to-Earnings relation has been negative, as the company lost money. It ranks last-in-rank when measured against peer companies.
  • Comparing the current stock price with the past twelve-months revenues gives a low relationship. One common cause includes profitability being poor. It looks rather normal in relation to rival firms.
  • The stock price is at or below the accounting book value. Unless profitability is really low, the stock may be selling a t a discount. Pay attention to the other key indicators for hints. The company remains well ranked against peer firms.
  • In the past twelve months, the operating business lost plenty of money. It happens to be last-in-rank when measured against industry peers.
  • In an alternate metric of bang for the buck, the company has usually shown an extremely low earnings power ability when measured against the current stock price and financial position. Profitability is significantly in dispute. It's still a disappointment compared to peer companies.

Total score: 2.7


BIMI logos

Company at a glance: BIMI International Medical, Inc. (BIMI)

Sector, industry: Healthcare, Pharmaceutical Retailers

Market Cap: 0.01 billions

Revenues TTM: 0.03 billions

BIMI International Medical Inc., together with its subsidiaries, engages in the retail and wholesale distribution of medical devices, and pharmaceutical and other healthcare products in the People's Republic of China. The company operates in four segments: Wholesale Pharmaceuticals, Wholesale Medical Devices, Medical Services, and Retail Pharmacies. It distributes Stryker spinal products, Olympus endoscopes, imported imaging products, and diagnostic imaging equipment to drug stores, private clinics, pharmaceutical dealers, and hospitals in the Southwest region of the People's Republic of China. The company also distributes generic drugs, Chinese herbal medicine, biochemical drugs, raw ingredients for pharmaceutical products, antibiotics, cardiovascular drugs, and anti-obesity medicines. In addition, it offers prescription and over-the-counter drugs, nutritional supplements, health foods, sundry products, traditional Chinese medicines, personal and family care products, medical devices, and miscellaneous items under the Lijiantang Pharmacy brand name. Further, the company provides medical services in the hospitals, as well as IT research and development services. It sells its medicine and other healthcare products to customers through its directly owned stores. The company was formerly known as BOQI International Medical Inc. and changed its name to BIMI International Medical Inc. in June 2021. BIMI International Medical Inc. was incorporated in 2000 and is based in Chongqing, the People's Republic of China.

Awarener score: 3.1

Conclusion

The higher the Awarener score, the more bang you get for the buck. It measures how much genuine funds the company generates for the stock price paid (Very poor), the business stability (Bottom) and growth (Superb), and the company's inclination to return cash to the stockholders (Bottom).